Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Net Cash Flow (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Net Cash Flow for 14 consecutive years, with -$4.6 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 47.99% to -$4.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$8.6 million through Dec 2025, down 12.46% year-over-year, with the annual reading at -$8.6 million for FY2025, 12.46% down from the prior year.
  • Net Cash Flow hit -$4.6 million in Q4 2025 for Corcept Therapeutics, down from $22.7 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $233.6 million in Q1 2023 to a low of -$127.6 million in Q2 2023.
  • Historically, Net Cash Flow has averaged $2.1 million across 5 years, with a median of -$2.7 million in 2021.
  • Biggest five-year swings in Net Cash Flow: soared 2107.68% in 2022 and later tumbled 506.64% in 2023.
  • Year by year, Net Cash Flow stood at -$17.1 million in 2021, then skyrocketed by 194.23% to $16.1 million in 2022, then soared by 45.42% to $23.4 million in 2023, then tumbled by 137.9% to -$8.9 million in 2024, then soared by 47.99% to -$4.6 million in 2025.
  • Business Quant data shows Net Cash Flow for CORT at -$4.6 million in Q4 2025, $22.7 million in Q3 2025, and $11.1 million in Q2 2025.